What is Redesign Science?
Redesign Science specializes in simulating biomolecular systems through physics-based atomic-level molecular dynamics. Their proprietary NUVO technology platform uniquely combines physics simulation with generative AI. This integration powers their internal therapeutics pipeline, which is focused on creating first-in-class small molecule Targeted Protein Interaction Modulators (TPIMs). By targeting the structural protein interactome, Redesign Science aims to achieve greater control over cellular biology using innovative small molecules, thereby advancing drug discovery and addressing complex biological challenges.
How much funding has Redesign Science raised?
Redesign Science has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2021): $15M with participation from Refactor Capital, Third Kind Venture Capital, Notation Capital, 5Y Capital, Collaborative Fund, HawkTail, Acequia Capital, and Preface Ventures
Key Investors in Redesign Science
Refactor Capital
Refactor Capital is an early-stage venture capital firm that focuses on investing in hard tech founders addressing fundamental human problems, providing substantial funding and direct access to its founding partner.
Third Kind Venture Capital
Third Kind Venture Capital is a venture capital firm specializing in early-stage investments, particularly in consumer internet, software, and financial services sectors.
Notation Capital
Notation Capital is a first-check venture fund based in Brooklyn, NY, focusing on very early-stage technical teams and providing capital and support for go-to-market strategies.
What's next for Redesign Science?
With the recent influx of major strategic investment, Redesign Science is poised for significant expansion. The company's focus on integrating advanced simulation techniques with AI for drug discovery positions it at the forefront of therapeutic innovation. This capital infusion will likely fuel the advancement of their internal pipeline, enabling them to tackle challenging biological targets and accelerate the development of novel small molecule therapies. The company's commitment to targeting the protein interactome suggests a strategic push towards precision medicine and novel therapeutic modalities.
See full Redesign Science company page
